Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, up 167% from $1.05 million in the prior-year period. The increase reflects expansion of its contract development and manufacturing organization (CDMO) operations, including the February acquisition of Recipharm Israel. The company reported an operating loss of $6.56 million and a net loss of $390,000, with the latter benefiting from a $6.4 million noncash bargain purchase gain related to the acquisition.
Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025, including an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees. The company generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, Scinai expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028.
The revenue growth and committed order backlog signal that Scinai’s CDMO strategy is gaining commercial traction, which is critical for a company that also funds an immunology-focused therapeutic development platform. The Recipharm Israel acquisition appears to have immediately boosted manufacturing capacity and customer access, while the bargain purchase gain flattered net results. However, the operating loss of $6.56 million underscores that the CDMO business is not yet self-sustaining. The $8.32 million in committed orders, if converted to revenue, provides greater visibility into future top-line performance and could help narrow losses. The October financing extends the cash runway, but Scinai will need to continue growing orders and executing on manufacturing contracts to avoid future dilution. For investors, the key takeaway is that Scinai is transitioning from a pure therapeutic developer to a hybrid CDMO-therapeutics company, with the CDMO segment now driving revenue growth. The expanded U.S. customer agreement is particularly important because it demonstrates traction in the large U.S. biotech market. To view the full press release, visit https://ibn.fm/1OlnB. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
InvestorWire, a specialized communications platform, distributes such announcements through InvestorWire and is part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and other services. Full terms and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
